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Abstract
Background: Transcriptome analysis is of great interest in clinical research, where significant differences between
individuals can be translated into biomarkers of disease. Although next generation sequencing provides robust,
comparable and highly informative expression profiling data, with several million of tags per blood sample,
reticulocyte globin transcripts can constitute up to 76% of total mRNA compromising the detection of low
abundant transcripts. We have removed globin transcripts from 6 human whole blood RNA samples with a human
globin reduction kit and compared them with the same non-reduced samples using deep Serial Analysis of Gene
Expression.
Results: Globin tags comprised 52-76% of total tags in our samples. Out of 21,633 genes only 87 genes were
detected at significantly lower levels in the globin reduced samples. In contrast, 11,338 genes were detected at
significantly higher levels in the globin reduced samples. Removing globin transcripts allowed us to also identify
2112 genes that could not be detected in the non-globin reduced samples, with roles in cell surface receptor
signal transduction, G-protein coupled receptor protein signalling pathways and neurological processes.
Conclusions: The reduction of globin transcripts in whole blood samples constitutes a reproducible and reliable
method that can enrich data obtained from next generation sequencing-based expression profiling.
Background
Transcriptomics technologies have successfully been used
for biomarker discovery and the study of physiological and
pathophysiological mechanisms [1]. Recently, advances in
sequencing technology have allowed for direct identifica-
tion of transcript specific sequences (tags) that are digitally
counted, and the analysis of differences in gene expression
with unprecedented accuracy [2]. One specific application
of next generation gene expression analysis is DeepSAGE, a
tag sequencing method on the Illumina high-throughput
sequencing platform that is analogous to LongSAGE [3].
Such sequencing-based technologies offer distinct advan-
tages over expression micro-arrays, such as a higher
dynamic range, the increased power for detection of
low abundance transcripts, and the detection of novel
transcripts and transcript variants [4,5]. Furthermore, next
generation sequencing technologies show less variation
between different study sites than microarray technology
and are not content-limited [6].
Transcriptome analysis of peripheral blood is of great
interest for clinical research; where significant differences
between samples obtained in a minimally invasive and
cost-effective manner can be translated into gene signa-
tures of disease stage, drug response and toxicity [7]. Blood
comes into contact with almost every tissue and organ of
the human body and due to its cellular composition it can
reflect both physiological and pathogenic stimuli. Gene
expression differences in peripheral whole blood have been
used to determine signatures related to acute myeloid leu-
kaemia [8], but also in neuropsychiatric disorders and
Huntington’s disease where significant correlation was
found between blood and brain gene expression [9,10].
Furthermore disease signatures can be robust across tissues
and experiments and in a large meta-analysis study
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that gene expression profiles in various tissues from the
same disease were more similar than gene expression pro-
files from identical tissues from different diseases [11].
Furthermore, 80% of genes expressed in peripheral blood
cells are shared with other important tissues [12]. These
results suggest that transcriptome analysis of the blood is
often informative even when the originating pathology
stems from a different tissue.
Blood is composed of three main cell types. The main
component is red blood cells (95%), including the progeni-
tor erythrocytes called reticulocytes, followed by platelets
(5%) and white blood cells (< 1%). While white blood cells
make up the minority, they are the most informative and
in the past, many studies have been performed on the iso-
lated white blood cell fraction. However, white blood cell
isolation kits can induce a technical bias that can con-
found the original expression profile of the samples and
delayed sample processing can affect gene expression pro-
files [13,14]. This means that white blood cell separation
protocols require quick and accurate processing, which
can be difficult in a clinical setting. The expression profile
of a sample is better preserved by a whole blood collection
method, like the PAX gene blood RNA system [15].
Another advantage of this system is that samples can be
frozen for up to 2 years without affecting the expression
profile [16]. However, cell sorting and counting is not pos-
sible because blood cells are lysed directly after collection.
Therefore, abundant transcripts in abundant cell types
may conceal the more interesting less abundant transcripts
from less abundant cell types. Particularly, the presence of
globin transcripts originating from reticulocytes in whole
blood samples may limit the sensitivity of gene expression
profiling experiments [14], since globin transcripts can
constitute up to 70% of the total whole blood mRNA
population [17]. While in microarray experiments the pre-
s e n c eo fg l o b i nt r a n s c r i p t sm a yr e d u c et h ea m o u n to f
fluorescent label available for other transcripts but other-
wise just results in a saturated spot on the microarray, the
high abundance of globin transcripts is more of a concern
in sequencing-based expression profiling studies. Since
measuring absolute abundance, globin transcripts will be
sequenced over and over again, while limiting the coverage
of other transcripts.
To deal with the abundance of globin transcripts in
whole blood mRNA, several globin reduction protocols
have been successfully used in gene expression studies
[18-21]. The removal of alpha and beta globin mRNA
can be achieved by selective hybridization of biotinylated
globin sequence specific oligos with the globin transcripts
and depleting them from the total mRNA population
through magnetic beads [17]. Another approach devel-
oped by Affymetrix and PreAnalytiX utilizes 3’ specific
PNAs to inhibit reverse transcription during cDNA
synthesis. Alternatively, a high abundance transcript
depletion protocol adopts the properties of the Kamtch-
aka crab duplex specific nuclease to selectively reduce
the most abundant RNA transcripts [22].
Our aim in the present study is to investigate the
effect of globin transcript reduction on the specificity
and sensitivity of digital gene expression profiling (deep
SAGE).
Results
Globin transcripts can successfully be reduced in whole
blood samples
To investigate whether the RNA quality was affected by
globin reduction, the RNA Integrity Number (RIN) value
was determined for each sample (summarized in Table 1)
with a RIN value of 10 representing the highest RNA qual-
ity. On average, the RIN value was slightly lower in the
globin-reduced samples compared to the non-reduced
samples indicating a minor reduction in RNA quality.
Additionally, we measured RNA concentrations before
and after globin reduction and observed an RNA yield loss
of 5-9%. General sequencing and alignment statistics are
given in Table 1. To verify if globin reduction was success-
ful, the percentage of globin transcripts was determined in
the reduced and non-reduced samples. The most abun-
dant transcripts in the non-reduced samples corresponded
to globin alpha1 (HBA1), globin beta (HBB) and globin
alpha2 (HBA2) (Figure 1). The percentage of globin tran-
scripts constituted on average 60% (52-76%) of total
reported alignments and for the reduced samples this
dropped to 0.1% - 0.4% (Table 1), demonstrating the effi-
ciency of the globin reduction protocol. The two tran-
scripts that were most abundant after the globin
transcripts, lysozyme (LYZ)a n dr i b o s o m a lp r o t e i n
(RPLP2) transcripts were detected at higher levels in the
globin-reduced samples. In order to validate the next gen-
eration sequencing results we performed qPCR for HBA
and HBB for 4 non reduced and reduced samples and the
results confirmed the next generation sequencing results
(see Additional file 1).
To examine the reproducibility of globin reduction we
performed a logarithmic transformation on the count
data from the 6 globin reduced samples and calculated
the correlation. Correlation values ranged from 0.88 to
0.94, showing good reproducibility after globin reduction
(Additional file 2).
Differential Gene Expression Differences between Globin
Reduced and Non-Reduced Samples
To investigate if more genes could be identified after glo-
bin reduction we used the edgeR Bioconductor statistical
R package to examine differential gene expression
between the 6 globin reduced and 6 non-reduced sam-
ples. We identified 21,633 uniquely expressed genes in
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detected at significantly higher levels (FDR 1%) in the
globin reduced samples (Figure 2). There were 87 genes
detected at significantly lower levels in the globin
reduced samples. The transcripts that were the most sig-
nificantly decreased (p-value) were the pseudogene
CXorf25 and the 4 globin transcripts globin delta (HBD),
hemoglobin beta (HBB), hemoglobin alpha 1(HBA1),
hemoglobin alpha 2 (HBA2) (see Table 2). Furthermore,
82 other non-globin transcripts were significantly
reduced by the globin reduction procedure (Additional
File 3).
To examine why 83 non-globin transcripts were reduced
by the globin reduction procedure, we examined possible
non-target specific hybridization of the globin oligos. Using
the sequences of the ten biotinylated oligonucleotides from
the globin reduction kit we performed a blastn search
against the human mRNA reference genome but only the
4 globin transcripts that were found to be most signifi-
cantly decreased in our globin-reduced samples showed
significant hits in blastn. Moreover, oligonucleotide
sequences were analyzed with RNAhybrid, an online tool
for determining the minimum free hybridization energy
between a long and a short RNA [23] but no conclusive
evidence was found for non-specific hybridization between
oligonucleotides from the globin reduction kit and the 83
non-globin transcripts that were reduced in our globin-
reduced samples. Finally we wanted to investigate if any of
the 83 transcripts could have been co-captured with the
globin transcripts. Hence we investigated whether there
was sequence homology between the 83 top reduced tran-
scripts and the globin transcripts but there was no indica-
tion of co-capturing based on sequence homology.
Furthermore, more than half the transcripts reported as
non-specifically detected at lower levels were derived from
pseudogenes or expressed at very low levels.
Transcripts detected in globin-reduced samples only
From the total number of 21,633 transcripts discovered in
our SAGE experiments, 10,368 were expressed above the
threshold of at least 5 tags in 5 out of the 6 samples in
both the globin reduced and non-reduced group. We iden-
tified 2,112 transcripts in the globin-reduced samples that
were not expressed above the threshold in the non-
reduced samples and 32 transcripts in the non-globin
reduced samples that could not be detected in the globin-
reduced samples (see Figure 3). Additionally, 9,121 tran-
scripts were detected in globin-reduced samples only but
did not reach the threshold (low abundance transcripts).
Increasing the threshold tag number resulted in a higher
number of genes detected by the globin reduced samples
while the number of genes only detected in non-reduced
samples remained approximately the same. Furthermore
increasing the threshold resulted in less genes identified
by both groups.
Functional enrichment and gene biotype analysis
For the 2,112 transcripts identified in the globin reduced
samples only, we performed gene ontology (GO) term
enrichment analysis using the online DAVID Bioinfor-
matics Resources 6.7 [24] (see Table 3). The GO terms
that were most significantly enriched were “metal and ion
binding” and “DNA binding”, the latter including genes
encoding for proteins with roles in transcription and regu-
lation of transcription. We also performed the same
enrichment analysis for the 9,121 transcripts that did not
reach the more stringent threshold. This group of genes
also showed significant enrichment for metal and ion bind-
ing proteins. Additionally, we observed enrichment in
Table 1 Sequence Statistics and RNA qualities
Samples Non- globin reduced Globin-reduced
123456123456
RIN 8.1 7.7 7.1 6.9 7.3 8.8 7.6 7.2 6.7 6.9 7 8.2
Tag numbers 29.2
.10
6 13.2
.10
6 32.0
.10
6 11.6
.10
6 13.6
.10
6 10.1
.10
6 16.5
.10
6 28.7
.10
6 15.9
.10
6 15.3
.10
6 15.9
.10
6 14.9
.10
6
Non- aligned 1.27% 5.63% 1.43% 13.80% 5.64% 1.92% 3.64% 2.95% 3.37% 3.29% 3.45% 3.38%
Aligned 89.9% 84.4% 89.9% 80.1% 89.1% 91% 78.3% 78.9% 78.4% 78.9% 77.6% 77.5%
Globin tags 60.1% 52.1% 57.2% 69.6% 76% 71% 0.3% 0.4% 0.4% 0.2% 0.4% 0.1%
Quality of RNA depicted by RNA integrity numbers (RIN) for the 6 non-globin reduced and globin reduced samples. The number of tags, percentages of aligned
and non-aligned sequences, and relative number of globin tags are shown as percentage of the total number of aligned tags.
HBA1 HBA1
Hemoglobin alpha 1 - HBA1 (32%)
Hemoglobin beta - HBB (15%)
Hemoglobin alpha 2 - HBA2 (13%)
Residual mRNA population (40%)
HBA1
HBB HBA2
Residual
mRNAs
Figure 1 Transcript abundance in the non-globin reduced
samples. Pie chart showing the most abundant transcripts in whole
blood (average of 6 samples). Hemoglobin alpha 1 (HBA1),
hemoglobin beta (HBB) and hemoglobin alpha 2 (HBA2) comprise
the majority of transcripts.
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duction proteins, G-protein coupled receptors and proteins
involved in neurological processes. Since these transcripts
are present in low copy numbers in our samples, these
transcripts would benefit from globin reduction and even
greater depth of sequencing.
There are around 20,000 protein-coding genes that
together comprise only 2% of the human genome [25].
However, a large fraction of transcripts map outside
known protein coding genes [26] and it is becoming
clear that non-protein-coding RNAs play critical roles as
transcriptional, post-transcriptional and chromatin-mod-
ifying regulators [27]. As such, we were interested in
characterizing the gene biotype of the 21,633 transcripts
identified in our gene expression analysis (see Figure 4).
We analyzed the transcripts according to the groups
defined in Figure 3. The majority of transcripts from all
three groups were protein coding transcripts. However,
there were subtle differences in the identified tran-
scripts. The 2112 transcripts that were uniquely identi-
fied in the globin-reduced samples contained slightly
elevated numbers of pseudogenes, processed transcripts
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Figure 2 Differential expression of non-globin reduced versus globin reduced whole blood samples. A. MA-plot (log concentration on x-
axis, log fold-change on y-axis) showing that the majority of differentially expressed genes (P value < 0.01, indicated in red) are up-regulated
while the 4 globin genes showed the strongest reduction. Genes with zero expression in one of the groups are shown on the left end of the
plot. HBD: hemoglobin delta, HBB: hemoglobin beta, HBA1: hemoglobin alpha 1, HBA1: hemoglobin alpha 2. CXorf25 has a logConc of -18.79 and
a logFC of -14.3 and is not shown on this graph. B. Heatmap of normalised expression values of 21633 genes across the 6 non reduced and 6
reduced (R) samples where green depicts high expression and red low expression values.
Table 2 Top ten most differentially expressed transcripts
Gene Description Gene name logConc
1 logFC
2 pValue FDR
Pseudogene CXorf25 -18.79 -14.3 2.10e-54 3.68e-50
Globin Alpha1 HBA1 -5.19 -7.59 7.48e-34 6.53e-30
Globin Alpha2 HBA2 -6.43 -7.51 2.12e-33 1.23e-29
Globin Beta HBB -5.99 -6.76 3.82e-29 1.66e-25
Globin Delta HBD -12.87 -6.05 4.37e-25 1.52e-21
APX/Shroom Family SHROOM4 -17.84 -5.37 6.66e-20 1.93e-16
Ataxia/Rad3 ATR -15.71 4.57 6.80e-17 1.69e-13
Pseudogene RP11-431J24.4 -21.08 6.1 9.66e-17 2.10e-13
Trub sudouridine synthase TRUB1 -19.14 4.83 6.43e-16 1.24e-12
Pseudogene CTD-2165H16.1 -18.82 4.71 1.48e-15 2.58e-12
The 4 most abundant globin transcripts are in the top five of differentially down-regulated transcripts (
1 Log Concentration - Overall concentration for a tag
across the two groups compared.,
2 Log Fold-change - The log-fold change difference for the counts between the groups compared.).
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Page 4 of 9and large intergenic non-coding RNAs (lincRNAs). The
9121 transcripts whose tag numbers were too low to be
consistently ascribed to either of the experimental
groups contained relatively more pseudogenes.
Sequencing Depth vs. Globin Reduction - Genes
Discovered
The previous results showed that by reducing the num-
ber of globin transcripts before sequencing, the number
of different transcripts that can be identified increases.
Next, we investigated how much additional sequencing is
required to achieve this effect of globin reduction just by
sequencing non-globin reduced samples at a greater
depth. For this purpose we compared results from non-
globin reduced RNA samples that were sequenced at
high and low sequencing depth. At two times higher
sequencing depth, the reported alignments as well as the
number of identified transcripts for each of the samples
increased to the level of the globin reduced samples
(Table 4). The number of 13,000 detected transcripts in
globin-reduced samples is achieved at a sequencing
depth of ~15 million reads while the same number of
transcripts is detected at a sequencing depth of ~25 mil-
lion reads in the non-globin reduced samples. In silico
analysis was performed to determine at which sampling
rate the threshold of at least 5 tags in 5 out the 6 samples
was reached. The difference in detected transcripts
between the reduced and non-reduced samples at any
given sequencing depth remained equal, indicating that
even at a very large numbers of reads (> 60 million reads)
Table 3 GO term enrichment analysis using DAVID
GO: Term Count % of genes P value
MF Ion binding 383 23.7 7.90e-6
MF Cation binding 380 23.6 4.30e-6
MF Metal ion binding 379 16.4 2.20e-6
MF Transition metal ion binding 272 16.9 9.80e-7
MF Zinc ion binding 229 14.2 3.50e-6
MF DNA binding 214 13.3 9.50e-4
BP Regulation of transcription 214 13.3 8.40e-2
CC Intracellular non membrane bound organelle 210 13.0 1.30e-2
BP Transcription 183 11.3 2.50e-2
CC Plasma membrane part 176 10.9 3.70e-2
Top 10 Gene Ontology terms found enriched by the DAVID online analysis tool in the 2,112 transcripts uniquely found in the globin reduced samples. P-value
reflects the P-value from the hypergeometric test. CC-Cellular Component, BP-Biological process, MF-Molecular function.
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Figure 4 Gene biotype distribution in transcripts with and
without globin reduction. Percentage of identified transcripts in
the non-globin reduced and globin-reduced samples; low
abundance transcripts consist of transcripts detected at levels too
low to be assigned to any of the two previous groups. The 9121
low abundance transcripts contain relatively more processed
transcripts, pseudogenes, large intergenic non coding RNAs
(lincRNAs) and miscellaneous RNAs (miscRNAs). We statistically
compared the distribution of the number of transcripts over the
different categories with a chi-square test and all pairwise
comparisons were highly significant (p < 2.2e-16).
Figure 3 Venn diagram displaying the number of transcripts in
at least 5 out of 6 samples at a level of 5 tags or more.
Reducing the globin transcripts increases the number of transcripts
that can be reliably detected (2112 genes). 9121 genes were not
consistently expressed in either group.
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Figure 5).
Discussion
We performed globin transcript reduction on RNA from
human peripheral blood to investigate if this improved
the sensitivity of SAGE digital gene expression profiling.
In the non-reduced samples, globin percentages were
highly variable between samples and ranged from 52%
to 76%. These numbers match previous reports for glo-
bin transcript abundances in blood [17]. The globin
reduction process with biotinylated oligonucleotides
complementary to globin transcripts was successful
s i n c et h e r ew a sa>9 9 . 6 %r e d u c t i o ni ng l o b i nt r a n -
scripts. This was consistent with previous studies [28].
We observed that after globin reduction there was a
slight decrease in total RNA quality as well as an RNA
yield loss of 5-9%. The slight reduction in RNA quality
and yield had no effect on the quality of the data. From
the 21,633 transcripts that were detected across all 12
samples, 11,633 transcripts were detected at significantly
higher levels in the 6 globin reduced samples, while only
87 transcripts were reported as detected at significantly
lower levels. We can not explain why there were tran-
scripts, other than the globin transcripts, found to be
expressed at lower levels in the globin reduced samples.
In silico analysis showed that this was not likely due to
cross hybridization with the globin transcripts or with
the globin oligonucleotides from the globin reduction
kit.
We detected robust expression of 2112 transcripts in
g l o b i nr e d u c e ds a m p l e st h a tc o u l dn o tb ed e t e c t e di n
non-globin reduced samples. This is similar to what has
been previously reported using classical microarray gene
expression platforms [17]. The important advantage of
more detectable transcripts is that there will be increased
statistical power to detect differences between samples.
Furthermore, this increased number of detected tran-
scripts after globin reduction provides more information
about low abundance transcripts that could give new
insights into the underlying disease mechanism.
The reduction of globin transcripts provides a practical
and reproducible method for improving the number of
transcripts detected in human peripheral whole blood
samples, and reduces required sequencing capacity by a
factor two. Deep SAGE is a technique that detects short
tags of 21-22 base pairs representing specific transcripts.
For this reason the data complexity is lower compared to
other digital gene expression profiling techniques such as
whole transcriptome sequencing (RNA-seq). For RNA-
s e q ,w h e r et h ea i mi st oa l s oi dentify all the transcript
isoforms, saturation is definitely not reached at 25 million
reads, which would make globin transcript reduction in
blood even more advantageous for RNA-seq.
Conclusions
The reduction of globin transcripts together with whole
blood collection methods, such as the PAX system, con-
stitutes a reproducible and reliable method that
increases the number of transcripts detected in next
generation sequencing-based gene expression profiling.
This will increase the statistical power to detect disease
relevant signatures in patient-control studies.
Table 4 Number of transcripts identified across different sequencing depths
Group Non-reduced Reduced
Samples Sample1
Low
Sample2
Low
Sample1
High
Sample2
High
Sample1 Sample2
Total number of sequences 7.8
.10
6 11.6
.10
6 29.2
.10
6 32.0
.10
6 16.5
.10
6 15.9
.10
6
Reported Alignments 4.7
.10
6 5.5
.10
6 23.6
.10
6 25.6
.10
6 9.8
.10
6 9.4
.10
6
Transcripts Detected 9,823 9,003 13,085 12,738 13,302 12,831
Two non-globin-reduced samples were sequenced twice, at low and high sequencing depths, and compared to the sequencing results from the same samples
with reduction of the globin transcripts.
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Figure 5 Number of transcripts detected at increased sampling
rate. In silico analysis using the sum of aligned reads (total number
of reads ~60 million) across each group (reduced, non-reduced). A
random subset of these aligned reads is then used to find the
number of detected transcripts across the two sample groups over
the 5 tag, 5 out of 6 samples threshold. The plot shows that at
similar sequencing depths, there is a consistently higher number of
transcripts detected in the globin reduced samples compared to
the non-globin reduced samples.
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Blood Collection & RNA isolation
Samples from six healthy individuals of Caucasian decent
(4 females, 2 males) aged from 39 to 70 years old were col-
lected after informed consent and with ethical approval.
Whole blood was drawn into PAX gene tubes (Qiagen,
Venlo, The Netherlands) and inverted 10 times. Samples
were allowed to equilibrate at room temperature for 2
hours, placed at -20°C overnight and stored at -80°C until
further processing. Before total RNA extraction, samples
were thawed overnight at 4°C and total RNA was isolated
using the PAX RNA isolation kit following the manufac-
turer’s instructions, including DNAse treatment. RNA
quality and the RIN values were determined using the
RNA Nano LabChip assay (Agilent Technologies, Santa
Clara, CA, USA). The concentration of each sample was
validated using the Nanodrop spectrophotometer (Nano-
Drop Technologies, Wilmington, DE, USA).
Globin Reduction
From each sample, 1.5 μg of total RNA was treated using
the GLOBINclear™ Human Kit (Ambion, Austin, TX,
USA) according the manufacturer’s instructions. The kit
contains 10 globin sequence specific biotinylated oligonu-
cleotides http://www.freepatentsonline.com/y2006/
0257902.html. Transcripts hybridized to the oligonucleo-
tides are removed through streptavidin magnetic beads.
Concentration and quality of the samples were checked as
described above.
Quantitative Real-Time PCR
cDNA was synthesized from 1 μg of total RNA using the
T r a n s c r i p t o rF i r s tS t r a n dc D N AS y n t h e s i sK i t( R o c h e ,
Mannheim, Germany) with Random Hexamer primers at
50°C for 1 hour. The primer sequences designed to target
genes of interest and the reference gene ACTB are
described in Additional file 4. The qPCR was performed
using 1 μlo f4 xd i l u t e dc D N A ,2 xF a s t S t a r tU n i v e r s a l
SYBR Green Master mix (Roche), 2.5 pmol forward pri-
mer,2.5 pmol reverse primer and PCR grade water to a
total volume of 10 μl. The reaction was performed using
the LightCycler 480 (Roche) with initial denaturation
10 min. at 95°C, followed by 45 cycles of 10 sec. denatura-
tion at 95°C, 30 sec. annealing at 60°C and 20 sec. elonga-
tion at 72°C and final elongation was performed 5 min. at
72°C. This was followed by melting curve analysis from
60°C to 98°C with a ramp rate of 0.02°C per sec. The pri-
mer efficiencies and relative expression of the transcript
levels was determined using LinRegPCR_v11.3[29].
SAGE library production
SAGE libraries were produced according to the Illumina
protocol [6]. In short, after hybridization of 1 μgt o t a l
RNA to polydT magnetic beads (Dynabeads, Invitrogen
Life Technologies, Carlsbad, CA, USA), first and second
strand synthesis was performed. The beads attached to
the double stranded DNA were digested with NlaIII
restriction endonuclease to produce short double
stranded constructs starting at the most 3’ CATG of the
transcript. After ligation of the GEX adapter 1, the con-
struct was digested with MmeI to create a 21 base pair
fragment downstream of the GEX adapter 1. This frag-
ment was then ligated to GEX adapter 2 to complete the
cassette. The adaptor ligated constructs were amplified
by 15 cycles of PCR and the products were loaded on 6%
Novex TBE precast acrylamide gels (Invitrogen). The 96
base pair band corresponding to the NlaIII construct was
excised and purified from the gel slice using the soak and
crush method followed by ethanol precipitation. Sample
quality was checked on a DNA 1000 Lab-on-a-Chip (Agi-
lent). Sequencing was performed at the Leiden Genome
Technology Center on Illumina GA2 sequencer (Illu-
mina, San Diego, CA, USA). Purified samples were
diluted to 10 nM and loaded on a single lane of the flow
cell where, after cluster amplification, samples were put
through an ultra short 18 cycle sequencing run.
Sequence processing
Illumina Pipeline Software version 1.5 was used for data
sequence processing. The FASTQ files were analysed
using the open source GAPSS_B(v2) pipeline http://www.
lgtc.nl\GAPSS. All sequences were trimmed to 17 base
pairs to remove the first lower quality base pair from the
3’ end of the sequences. After trimming, the NlaIII recog-
nition site (CATG) was added to the 5’ end of the
sequence to create the complete 21-22mer nucleotide
sequences. Sequences were aligned using the Bowtie short
read aligner (version 0.12.7) against the UCSC hg19 refer-
ence genome, allowing for a maximum of one mismatch
and a maximum of two possible positions in the genome
(options: -k 1 -m 2 -n 1 –best –strata -solexa1.3-quals).
A custom Perl script was used to create reference region
files from the SAGE region files that were composed of
the overlapping tags from all samples. A second Perl script
was then used to link all individual region files to the
reference region file, reporting the number of tags in each
individual region of the reference region file. Finally, the
reference region file was annotated with transcript infor-
mation using BIOMART (Ensembl build 60). For all
reported downstream statistical and biological analysis
only sequences aligned to known exons were used. Ana-
lyses were performed at the gene level, and in case of mul-
tiple SAGE tags per gene, e.g. as a consequence of
alternative polyadenylation, tags were summed. The data
discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE33701 http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33701.
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To identify genes detected at lower or higher levels, data
files containing the count expression data were analyzed
using the edgeR package (version 2.0.5) [30,31] in R (ver-
sion 2.12.0). Data was normalized creating libraries of
equal size (11 million tags). To determine differences in
detection levels between the two groups an exact test for
the negative binomial distribution was used. The P-values
were adjusted for multiple testing using the Benjamini and
Hochberg’s approach for controlling the false discovery
rate (FDR) and genes were considered to be different
between reduced and non-reduced samples when the P
value was less than 0.01. For pathway enrichment analysis,
t h eo n l i n et o o lD A V I Dw a su s e d .T oi d e n t i f yg e n eb i o -
types, Ensembl genes IDs were uploaded to the BioMart
site and supplied gene biotype attributes (ENSEMBL build
60, Homo sapiens genome reference GRCH37.p2).
To examine if transcripts are uniquely and consistently
identified in the globin reduced or non-reduced samples
only, we applied a tag count threshold of 5 tags or more
and this threshold had to be met in 5 out of the 6 samples
in the respective group.
Additional material
Additional file 1: Hemoglobin qPCR results. qPCR results for the
hemoglobins before and after globin reduction. 4 non reduced and 4
reduced samples were loaded in triplicates and beta actin (ACTB) was
used as a reference gene.
Additional file 2: Correlation matrix for the Globin reduced samples.
Upper panels represent correlation values of log transformed data with
stars depicting significance. Lower panels contain scatter plots of log
transformed globin reduced samples.
Additional file 3: List of 87 down-regulated genes. List of 87 genes
detected at significantly lower levels in the globin reduced samples.
Additional file 4: qPCR primer Sequences. Primer sequences used for
qPCR validation of HBA, HBB transcript levels.
Acknowledgements
The blood samples were kindly provided by Prof Dr R.C. van der Mast and
Dr E. van Duijn at the Psychiatry Department, LUMC, The Netherlands. This
research was partly funded by the European Commission 7th Framework
Program, Project no. 261123, GEUVADIS, Project no. 201413, ENGAGE, by the
Centre for Medical Systems Biology within the framework of the Netherlands
Genomics Initiative/Netherlands Organisation for Scientific Research and
Dutch Centre for Biomedical Genetics.
Author details
1Center for Human and Clinical Genetics, Leiden University Medical Center,
Einthovenweg 20, 2333ZC, Leiden, The Netherlands.
2Leiden Genome
Technology Center, Leiden University Medical Center, Einthovenweg 20,
2333ZC Leiden, The Netherlands.
Authors’ contributions
AM carried out the sample processing, sequencing, statistical analysis, and
drafted the manuscript. JTDD participated in the design of the study and
helped to draft the manuscript. GJBVO participated in the design of the
study and helped to draft the manuscript PACTH participated in the design
of the study, the statistical analysis and helped to draft the manuscript.
WMCVRM conceived the study, and participated in its design and
coordination, and helped to draft the manuscript. All authors have read and
approved the final manuscript.
Received: 15 July 2011 Accepted: 18 January 2012
Published: 18 January 2012
References
1. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, et al:
Identifying blood biomarkers for mood disorders using convergent
functional genomics. Mol Psychiatry 2009, 14:156-174.
2. Shendure J, Ji H: Next-generation DNA sequencing. Nat Biotechnol 2008,
26:1135-1145.
3. Nielsen KL, Hogh AL, Emmersen J: DeepSAGE digital transcriptomics with
high sensitivity, simple experimental protocol and multiplexing of
samples. Nucleic Acids Res 2006, 34:e133.
4. Feng L, Liu H, Liu Y, Lu Z, Guo G, Guo S, et al: Power of deep sequencing
and agilent microarray for gene expression profiling study. Mol
Biotechnol 2010, 45:101-110.
5. van Iterson M, ’t Hoen PA, Pedotti P, Hooiveld GJ, Den Dunnen JT, Van
Ommen GJ, et al: Relative power and sample size analysis on gene
expression profiling data. BMC Genomics 2009, 10:439.
6. ’t Hoen PA, Ariyurek Y, Thygesen HH, Vreugdenhil E, Vossen RH, de
Menezes RX, et al: Deep sequencing-based expression analysis shows
major advances in robustness, resolution and inter-lab portability over
five microarray platforms. Nucleic Acids Res 2008.
7. Pahl A: Gene expression profiling using RNA extracted from whole blood:
technologies and clinical applications. Expert Rev Mol Diagn 2005, 5:43-52.
8. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van
Doorn-Khosrovani S, Boer JM, et al: Prognostically useful gene-expression
profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
9. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, et al: Genome-
wide expression profiling of human blood reveals biomarkers for
Huntington’s disease. PNAS 2005, 102:11023-11028.
10. Sullivan PF, Fan C, Perou CM: Evaluating the comparability of gene
expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet
2006, 141B:261-268.
11. Dudley JT, Tibshirani R, Deshpande T, Butte AJ: Disease signatures are
robust across tissues and experiments. Mol Syst Biol 2009, 5:307.
12. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA: The peripheral blood
transcriptome dynamically reflects system wide biology: a potential
diagnostic tool. J Lab Clin Med 2006, 147:126-132.
13. Muller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, et al:
Improvement of molecular monitoring of residual disease in leukemias
by bedside RNA stabilization. Leukemia 2002, 16:2395-2399.
14. Debey S, Schoenbeck U, Hellmich M, Gathof BS, Pillai R, Zander T, et al:
Comparison of different isolation techniques prior gene expression
profiling of blood derived cells: impact on physiological responses, on
overall expression and the role of different cell types. Pharmacogenomics
J 2004, 4:193-207.
15. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, et al:
Stabilization of mRNA expression in whole blood samples. Clin Chem
2002, 48:1883-1890.
16. Ovstebo R, Lande K, Kierulf P, Haug KB: Quantification of relative changes
in specific mRNAs from frozen whole blood - methodological
considerations and clinical implications. Clin Chem Lab Med 2007,
45:171-176.
17. Field LA, Jordan RM, Hadix JA, Dunn MA, Shriver CD, Ellsworth RE, et al:
Functional identity of genes detectable in expression profiling assays
following globin mRNA reduction of peripheral blood samples. Clin
Biochem 2007, 40:499-502.
18. Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, Choi D, et al: Gene
expression profiling of whole blood: comparison of target preparation
methods for accurate and reproducible microarray analysis. BMC
Genomics 2009, 10:2.
19. Wright C, Bergstrom D, Dai HY, Marton M, Morris M, Tokiwa G, et al:
Characterization of globin RNA interference in gene expression profiling
of whole-blood samples. Clin Chem 2008, 54:396-405.
20. Tian Z, Palmer N, Schmid P, Yao H, Galdzicki M, Berger B, et al: A Practical
Platform for Blood Biomarker Study by Using Global Gene Expression
Profiling of Peripheral Whole Blood. PLoS ONE 2009, 4.
Mastrokolias et al. BMC Genomics 2012, 13:28
http://www.biomedcentral.com/1471-2164/13/28
Page 8 of 921. Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL: A highly
standardized, robust, and cost-effective method for genome-wide
transcriptome analysis of peripheral blood applicable to large-scale
clinical trials. Genomics 2006, 87:653-664.
22. Bogdanova EA, Shagin DA, Lukyanov SA: Normalization of full-length
enriched cDNA. Mol Biosyst 2008, 4:205-212.
23. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R: Fast and effective
prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517.
24. Huang dW, Sherman BT, Lempicki RA: Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc
2009, 4:44-57.
25. Human Genome Sequencing Consortium: Finishing the euchromatic
sequence of the human genome. Nature 2004, 431:931-945.
26. Wright MW, Bruford EA: Naming ‘junk’: human non-protein coding RNA
(ncRNA) gene nomenclature. Hum Genomics 2011, 5:90-98.
27. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS: Non-coding RNAs:
regulators of disease. J Pathol 2010, 220:126-139.
28. Liu J, Walter E, Stenger D, Thach D: Effects of globin mRNA reduction
methods on gene expression profiles from whole blood. J Mol Diagn
2006, 8:551-558.
29. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den
Hoff MJB, et al: Amplification efficiency: linking baseline and bias in the
analysis of quantitative PCR data. Nucleic Acids Research 2009, 37.
30. Robinson MD, Smyth GK: Small-sample estimation of negative binomial
dispersion, with applications to SAGE data. Biostatistics 2008, 9:321-332.
31. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package
for differential expression analysis of digital gene expression data.
Bioinformatics 2010, 26:139-140.
doi:10.1186/1471-2164-13-28
Cite this article as: Mastrokolias et al.: Increased sensitivity of next
generation sequencing-based expression profiling after globin
reduction in human blood RNA. BMC Genomics 2012 13:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mastrokolias et al. BMC Genomics 2012, 13:28
http://www.biomedcentral.com/1471-2164/13/28
Page 9 of 9